

Table S3: Sensitivity analysis: changes in pneumococcal carriage prevalence, calculated without excluding children experiencing respiratory illness from carriage sample.

Age	Ethnicity	All serotypes			Vaccine-targeted serotype			Non-vaccine serotype		
		Pre-rollout ^{1,2}	Post-rollout ^{1,2}	RR ²	Pre-rollout ^{1,2}	Post-rollout ^{1,2}	RR ²	Pre-rollout ^{1,2}	Post-rollout ^{1,2}	RR ²
0-11 months	Bedouin	0.75 (0.66, 0.87)	0.46 (0.42, 0.50)	0.61 (0.52, 0.72)	0.39 (0.33, 0.44)	0.09 (0.08, 0.09)	0.22 (0.19, 0.26)	0.37 (0.32, 0.43)	0.37 (0.34, 0.41)	1.01 (0.86, 1.19)
	Jewish	0.40 (0.33, 0.48)	0.38 (0.35, 0.43)	0.96 (0.78, 1.19)	0.18 (0.15, 0.21)	0.04 (0.04, 0.05)	0.25 (0.20, 0.30)	0.22 (0.19, 0.27)	0.34 (0.31, 0.38)	1.52 (1.23, 1.87)
12-35 months	Bedouin	0.79 (0.74, 0.85)	0.45 (0.41, 0.49)	0.57 (0.50, 0.64)	0.50 (0.47, 0.54)	0.07 (0.06, 0.07)	0.13 (0.12, 0.15)	0.29 (0.27, 0.31)	0.38 (0.35, 0.42)	1.31 (1.16, 1.48)
	Jewish	0.49 (0.42, 0.56)	0.43 (0.39, 0.48)	0.89 (0.75, 1.06)	0.32 (0.28, 0.37)	0.03 (0.03, 0.03)	0.10 (0.08, 0.12)	0.16 (0.14, 0.19)	0.40 (0.36, 0.44)	2.47 (2.07, 2.94)

¹Carriage prevalence is measured as a proportion and standardized for ages 6 and 24 months within the <12 and 12-35 month age groups, respectively. The pre-PCV7 and PCV13 periods correspond to July 2004-June 2008 and July 2013-June 2016, respectively.

²All estimates (risk ratio for prevalence) are presented as mean (95% credible interval).